Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

CAPS Rating: 3 out of 5

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

Recs

3
Player Avatar yellowear (27.99) Submitted: 12/20/2008 12:32:36 PM : Outperform Start Price: $1.62 PLX Score: -12.28

Based on the news on the street and the performance of the stock at these levels, this company has the potential of reaching 2000% in the next 4 years. This stock has found a bottom like AKS did several years ago which reached a high of 70+ before it cratered. This is a 'Just about Perfect' time to start to buy this stock!

Member Avatar stockmd (< 20) Submitted: 10/30/2011 10:52:11 AM
Recs: 0

I agree with above now. Perfect time now to get loaded up ( deja vu!), almost 3 years later. Market cap of 500m . Was 2 billion in 2007 without any drugs approved by FDA.
Pfizer is backing the company. Protalix now has a CRL and PDUFA date in Feb, marketing agreement with Pfizer. Pfizer will also give milestone payments ( $50million on FDA approval). Drug is already being used ( special access granted after Genentech's Cerebrozyme shortage). No chance of viral contamination in Protalix drug as it is a plant cell based production ( unlike its competition)

Featured Broker Partners


Advertisement